Group A: Number of Participants Who Maintained Their Gross Motor Function Evaluated by Using the GMFC-MLD at Week 106 Compared With Matched External Control Group Data [Time Frame: Baseline up to Week 106]
Number of Participants With Change From Baseline in Gross Motor Function Evaluated by Using the GMFC-MLD at Week 106 [Time Frame: Baseline, Week 106]
Group A: Number of Participants With Decline From Baseline in GMFC-LMD of More Than 2 Categories [Time Frame: Baseline, Week 106]
Group A: Time to Decline From Baseline in GMFC-MLD of More Than 2 Categories [Time Frame: Baseline, Week 106]
Change From Baseline in Cerebrospinal Fluid (CSF) Sulfatides Levels at Week 106 [Time Frame: Baseline, Week 106]
Percent Change From Baseline in Cerebrospinal Fluid (CSF) Sulfatides Levels at Week 106 [Time Frame: Baseline, Week 106]
Group A: Number of Participants With Maintenance of Gross Motor Function at Week 106 Using Gross Motor Function Measure 88 (GMFM-88) Total Score [Time Frame: Baseline up to Week 106]
Time to Unreversed Decline From Baseline in GMFM-88 Total Score of Greater Than (>) 20 Points or Unreversed Decline to Less Than (<) 40 Points Whichever Occurs First [Time Frame: Baseline, Week 106]
Change From Baseline in GMFM-88 Total Score at Week 106 [Time Frame: Baseline, Week 106]
Group A: Number of Participants With GMFM-88 Total Score Decrease of <= 20 Points From Baseline and a Total Score >=40 Points at Week 106 [Time Frame: Baseline, Week 106]
Number of Participants With Change From Baseline in Expressive Language Evaluated by Using the Expressive Language Function Classification in Metachromatic Leukodystrophy (ELFC-MLD) Scale Categories at Week 106 [Time Frame: Baseline, Week 106]
Number of Participants With Treatment-emergent Adverse Event (TEAEs) [Time Frame: From start of study drug administration up to Week 106]
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values at Week 106 [Time Frame: Baseline up to Week 106]
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings at Week 106 [Time Frame: Baseline up to Week 106]
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values at Week 106 [Time Frame: Baseline up to Week 106]
Number of Participants With Clinically Significant Change From Baseline in Cerebrospinal Fluid (CSF) Laboratory Parameters at Week 106 [Time Frame: Baseline up to Week 106]
Number of Participants With Anti-Drug Antibody (ADA) Response to SHP611 [Time Frame: Baseline up to Week 106]
Number of Participants With IDDD Implantations [Time Frame: Baseline up to Week 106]
Number of Participants With Any IDDD Related Malfunctions [Time Frame: Baseline up to Week 106]
IDDD Longevity as Assessed by Time to IDDD Failure [Time Frame: Baseline up to Week 106]
Number of Participants With TEAE Related to IDDD and Surgical Procedure [Time Frame: Baseline up to Week 106]
